vs

Side-by-side financial comparison of Baird Medical Investment Holdings Ltd (BDMD) and UTAH MEDICAL PRODUCTS INC (UTMD). Click either name above to swap in a different company.

UTAH MEDICAL PRODUCTS INC is the larger business by last-quarter revenue ($9.0M vs $8.0M, roughly 1.1× Baird Medical Investment Holdings Ltd). UTAH MEDICAL PRODUCTS INC runs the higher net margin — 28.4% vs -142.7%, a 171.1% gap on every dollar of revenue. UTAH MEDICAL PRODUCTS INC produced more free cash flow last quarter ($3.4M vs $-3.2M).

Baird Medical Investment Holdings Ltd is a healthcare-focused investment holding company mainly operating in the Chinese market. It invests in and manages businesses covering in vitro diagnostic devices, medical consumables, and community healthcare services, serving clinical institutions and individual consumers.

Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...

BDMD vs UTMD — Head-to-Head

Bigger by revenue
UTMD
UTMD
1.1× larger
UTMD
$9.0M
$8.0M
BDMD
Higher net margin
UTMD
UTMD
171.1% more per $
UTMD
28.4%
-142.7%
BDMD
More free cash flow
UTMD
UTMD
$6.6M more FCF
UTMD
$3.4M
$-3.2M
BDMD

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
BDMD
BDMD
UTMD
UTMD
Revenue
$8.0M
$9.0M
Net Profit
$-11.4M
$2.6M
Gross Margin
82.1%
58.2%
Operating Margin
-131.3%
27.0%
Net Margin
-142.7%
28.4%
Revenue YoY
-1.2%
Net Profit YoY
-11.6%
EPS (diluted)
$0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BDMD
BDMD
UTMD
UTMD
Q4 25
$9.0M
Q3 25
$9.8M
Q2 25
$8.0M
$10.0M
Q1 25
$9.7M
Q4 24
$9.2M
Q3 24
$10.0M
Q2 24
$10.4M
Q1 24
$11.3M
Net Profit
BDMD
BDMD
UTMD
UTMD
Q4 25
$2.6M
Q3 25
$2.6M
Q2 25
$-11.4M
$3.0M
Q1 25
$3.0M
Q4 24
$2.9M
Q3 24
$3.6M
Q2 24
$3.5M
Q1 24
$4.0M
Gross Margin
BDMD
BDMD
UTMD
UTMD
Q4 25
58.2%
Q3 25
57.1%
Q2 25
82.1%
56.2%
Q1 25
57.0%
Q4 24
58.1%
Q3 24
58.0%
Q2 24
60.1%
Q1 24
59.7%
Operating Margin
BDMD
BDMD
UTMD
UTMD
Q4 25
27.0%
Q3 25
26.6%
Q2 25
-131.3%
32.1%
Q1 25
32.5%
Q4 24
32.0%
Q3 24
33.4%
Q2 24
33.1%
Q1 24
34.2%
Net Margin
BDMD
BDMD
UTMD
UTMD
Q4 25
28.4%
Q3 25
26.8%
Q2 25
-142.7%
30.6%
Q1 25
31.3%
Q4 24
31.7%
Q3 24
35.6%
Q2 24
33.2%
Q1 24
34.9%
EPS (diluted)
BDMD
BDMD
UTMD
UTMD
Q4 25
$0.80
Q3 25
$0.82
Q2 25
$0.94
Q1 25
$0.92
Q4 24
$0.86
Q3 24
$1.03
Q2 24
$0.98
Q1 24
$1.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BDMD
BDMD
UTMD
UTMD
Cash + ST InvestmentsLiquidity on hand
$85.8M
Total DebtLower is stronger
$8.4M
$225.0K
Stockholders' EquityBook value
$35.6M
$119.3M
Total Assets
$77.0M
$122.5M
Debt / EquityLower = less leverage
0.24×
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BDMD
BDMD
UTMD
UTMD
Q4 25
$85.8M
Q3 25
$84.3M
Q2 25
$82.2M
Q1 25
$83.3M
Q4 24
$83.0M
Q3 24
$88.5M
Q2 24
$89.2M
Q1 24
$93.8M
Total Debt
BDMD
BDMD
UTMD
UTMD
Q4 25
$225.0K
Q3 25
Q2 25
$8.4M
Q1 25
$269.0K
Q4 24
$282.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BDMD
BDMD
UTMD
UTMD
Q4 25
$119.3M
Q3 25
$118.3M
Q2 25
$35.6M
$117.5M
Q1 25
$117.0M
Q4 24
$117.4M
Q3 24
$124.2M
Q2 24
$124.1M
Q1 24
$127.7M
Total Assets
BDMD
BDMD
UTMD
UTMD
Q4 25
$122.5M
Q3 25
$122.0M
Q2 25
$77.0M
$120.8M
Q1 25
$122.5M
Q4 24
$122.5M
Q3 24
$129.7M
Q2 24
$130.0M
Q1 24
$135.4M
Debt / Equity
BDMD
BDMD
UTMD
UTMD
Q4 25
0.00×
Q3 25
Q2 25
0.24×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BDMD
BDMD
UTMD
UTMD
Operating Cash FlowLast quarter
$-3.2M
$3.5M
Free Cash FlowOCF − Capex
$-3.2M
$3.4M
FCF MarginFCF / Revenue
-40.7%
37.2%
Capex IntensityCapex / Revenue
0.6%
1.2%
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BDMD
BDMD
UTMD
UTMD
Q4 25
$3.5M
Q3 25
$3.9M
Q2 25
$-3.2M
$2.9M
Q1 25
$4.5M
Q4 24
$2.9M
Q3 24
$3.9M
Q2 24
$2.8M
Q1 24
$5.3M
Free Cash Flow
BDMD
BDMD
UTMD
UTMD
Q4 25
$3.4M
Q3 25
$3.9M
Q2 25
$-3.2M
$2.8M
Q1 25
$4.3M
Q4 24
$2.9M
Q3 24
$3.8M
Q2 24
$2.7M
Q1 24
$5.3M
FCF Margin
BDMD
BDMD
UTMD
UTMD
Q4 25
37.2%
Q3 25
39.2%
Q2 25
-40.7%
28.4%
Q1 25
44.1%
Q4 24
32.0%
Q3 24
37.7%
Q2 24
25.5%
Q1 24
46.3%
Capex Intensity
BDMD
BDMD
UTMD
UTMD
Q4 25
1.2%
Q3 25
0.3%
Q2 25
0.6%
0.5%
Q1 25
1.9%
Q4 24
0.1%
Q3 24
0.9%
Q2 24
1.1%
Q1 24
0.2%
Cash Conversion
BDMD
BDMD
UTMD
UTMD
Q4 25
1.36×
Q3 25
1.47×
Q2 25
0.94×
Q1 25
1.47×
Q4 24
1.01×
Q3 24
1.08×
Q2 24
0.80×
Q1 24
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons